Posts by zzbiotech

New research finds vascular damage in mice with ALS contributes to early development of the neurodegenerative disease, while repairing damage delays disease progression LOS ANGELES, March 3, 2014 — Keck School of Medicine of USC neuroscientists have unlocked a piece of the puzzle in the fight against Lou Gehrig’s disease, a debilitating neurological disorder that…

Multi-site phase 2 clinical trials anticipated to begin recruiting patients in 2014 LOS ANGELES, October 24, 2013 — An experimental drug called 3K3A-APC appears to reduce brain damage, eliminate brain hemorrhaging and improve motor skills in older stroke-afflicted mice and stroke-afflicted rats with comorbid conditions such as hypertension, according to a new study from Keck…

Experimental drug may extend window for effective stroke treatment LA JOLLA, CA, August 8, 2012 — Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC) and further developed by biotech company ZZ Biotech. The clinical…

HOUSTON, Texas, August 8, 2012—ZZ Biotech, LLC today announced that it has commenced dosing healthy volunteers in a Phase 1 clinical study with 3K3A-APC, a recombinant variant of human activated protein C (APC), being developed for the treatment of acute ischemic stroke. The Phase 1 study is a randomized, double-blind, placebo-controlled, single-center trial that will…

Clinical safety trials in humans to start this summer LOS ANGELES, July 17, 2012 — A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy. Clinical trials to test…